changes made to the company /restructure are lifetime and has reduced the cost of revenue , it will end up having the same revenue as metrics with much less cost .Compare this to a company like Neuren that has 4 times the market cap with less than %20 of Mayne Revenue and that will tell you what restructure /cost reduction program can achieve for mayne pharma
Nexstllis growth 267% units sold 256330 units sold, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.97 |
Change
-0.285(5.43%) |
Mkt cap ! $407.0M | |||
| Open | High | Low | Value | Volume |
| $5.17 | $5.18 | $4.96 | $830.2K | 164.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1174 | $4.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.97 | 217 | 2 |
View Market Depth
| Last trade - 14.45pm 29/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |